To appraise the clinical and cost effectiveness of venetoclax in combination with rituximab within its marketing authorisation for treating relapsed or refractory chronic lymphocytic leukaemia.
 
Status In progress
Process STA pre-2018
ID number 1097

Provisional Schedule

Expected publication 20 March 2019

Project Team

Project lead Stephanie Callaghan

Email enquiries

Consultees

Companies sponsors AbbVie (venetoclax)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Bloodwise
  Chronic Lymphocytic Leukaemia Support Association
  Leukaemia CARE
  Lymphoma Action
Professional groups Association of Cancer Physicians
  British Society for Haematology
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Celltrion Healthcare Hungary (rituximab) – (confidentiality agreement not signed, not participating)
  Gilead Sciences (idelalisib)
  Janssen (ibrutinib)
  Napp Pharmaceuticals (rituximab) – confidentiality agreement not signed, not participating
  Roche Products (rituximab)
  Sandoz (rituximab) – (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
27 September 2018 Committee meeting: 1
25 April 2018 Invitation to participate
12 January 2018 - 09 February 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance